These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28419646)

  • 1. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hypocretin/orexin receptor blockade on drug-taking and ultrasonic vocalizations (USVs) associated with low-effort self-administration of cathinone-derived 3,4-methylenedioxypyrovalerone (MDPV) in rats.
    Simmons SJ; Martorana R; Philogene-Khalid H; Tran FH; Gentile TA; Xu X; Su S; Rawls SM; Muschamp JW
    Psychopharmacology (Berl); 2017 Nov; 234(21):3207-3215. PubMed ID: 28786030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1.
    Prince CD; Rau AR; Yorgason JT; España RA
    ACS Chem Neurosci; 2015 Jan; 6(1):138-46. PubMed ID: 25496218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans.
    Stoops WW; Strickland JC; Hatton KW; Hays LR; Rayapati AO; Lile JA; Rush CR
    Pharmacol Biochem Behav; 2022 Oct; 220():173466. PubMed ID: 36152876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration.
    España RA; Melchior JR; Roberts DC; Jones SR
    Psychopharmacology (Berl); 2011 Mar; 214(2):415-26. PubMed ID: 20959967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.
    Levy KA; Brodnik ZD; Shaw JK; Perrey DA; Zhang Y; España RA
    Psychopharmacology (Berl); 2017 Sep; 234(18):2761-2776. PubMed ID: 28667509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine.
    Bernstein DL; Badve PS; Barson JR; Bass CE; España RA
    Addict Biol; 2018 Sep; 23(5):1032-1045. PubMed ID: 28971565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cocaine place conditioning, chronic escalating-dose "binge" pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats.
    Zhou Y; Cui CL; Schlussman SD; Choi JC; Ho A; Han JS; Kreek MJ
    Neuroscience; 2008 Jun; 153(4):1225-34. PubMed ID: 18436386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential role of hypothalamic orexin/hypocretin neurons in reward seeking motivated by cocaine versus palatable food.
    Martin-Fardon R; Cauvi G; Kerr TM; Weiss F
    Addict Biol; 2018 Jan; 23(1):6-15. PubMed ID: 27558790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system.
    España RA; Oleson EB; Locke JL; Brookshire BR; Roberts DC; Jones SR
    Eur J Neurosci; 2010 Jan; 31(2):336-48. PubMed ID: 20039943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexin-mediated restoration of hippocampal synaptic potentiation in mice with established cocaine-conditioned place preference.
    Lu GL; Lee MT; Chiou LC
    Addict Biol; 2019 Nov; 24(6):1153-1166. PubMed ID: 30276922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.
    Simmons SJ; Gentile TA
    Brain Res; 2020 Mar; 1731():146164. PubMed ID: 30796894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of hypocretin attenuates extended access of cocaine self-administration in rats.
    Schmeichel BE; Matzeu A; Koebel P; Vendruscolo LF; Sidhu H; Shahryari R; Kieffer BL; Koob GF; Martin-Fardon R; Contet C
    Neuropsychopharmacology; 2018 Nov; 43(12):2373-2382. PubMed ID: 29703996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.